Deadline Boosts Colorectal Cancer Screening Uptake in TEMPO Trial

By João L. Carapinha

March 17, 2025

Are deadlines the secret to increasing colorectal cancer screening rates? The TEMPO trial, a nationwide randomized controlled trial in Scotland, evaluated the impact of two behavioral interventions on colorectal cancer screening uptake. These interventions included adding a deadline for returning faecal immunochemical tests (FIT) and using a problem-solving planning tool. The study found that including a deadline in the invitation letter significantly increased timely FIT returns and reduced the need for reminder letters. The planning tool had no positive effect. A 2-week deadline was identified as the most effective and acceptable option.

Key Insights from the TEMPO Trial

  • Deadline Effectiveness. Adding a deadline to the FIT invitation letter increased timely returns and reduced the need for reminder letters. The 2-week deadline was particularly effective in enhancing colorectal cancer screening rates.
  • Planning Tool Ineffectiveness. The planning tool did not improve FIT return rates and was even detrimental when used without a deadline.
  • Cost-Effectiveness. The deadline intervention is highly cost-effective, requiring minimal additional resources.

Understanding the Colorectal Screening Landscape

Colorectal cancer screening uptake is suboptimal globally, with about 50% participation in European FIT programs. Interventions like deadlines and planning tools could enhance participation. The TEMPO trial is the first to assess these interventions within a nationwide screening program.

Strategic Implications and Future Directions

Implementing deadlines could increase FIT returns and potentially save lives by facilitating earlier detection of colorectal cancer. Reducing reminder letters can lead to substantial cost savings for screening programs. Further studies should explore the effectiveness of deadlines in other screening contexts. They should also assess potential barriers to implementation, such as literacy levels and language barriers. For more insights into the effectiveness of these interventions, you can explore the article on The Lancet’s website here.

Reference url

Recent Posts

Positive ARTISTRY-2 Trial Results for BIC LEN HIV Regimen

By HEOR Staff Writer

December 17, 2025

BIC/LEN HIV Regimen Delivers Non-Inferior Results in ARTISTRY-2 Gilead Sciences announced positive topline results from the Phase 3 ARTISTRY-2 trial, demonstrating that the investigational BIC LEN HIV regimen
Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Patients

By HEOR Staff Writer

December 16, 2025

Accelerating Review for Transformative Multiple Myeloma Therapy The U.S. Food and Drug Administration (
CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals
The CHMP meeting highlights from December 2025 reveal major advancements in drug approvals. What were the key outcomes of the EMA's Committee for Medicinal Products for Human Use session held December 8-11? The committee recommended seven new medicines for approval. These target critical areas li...